Overview

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Status:
Completed
Trial end date:
2016-12-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Treatments:
Albumin-Bound Paclitaxel
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Erlotinib Hydrochloride
Paclitaxel